Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study) - Wikidata - wikimedia - TriplyDB

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)

http://www.wikidata.org/entity/Q37257345

about

Interventions for fatigue in Parkinson's disease Emerging approaches in Parkinson's disease - adjunctive role of safinamide Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date Current Experimental Studies of Gene Therapy in Parkinson's Disease Recent advances in treating Parkinson's disease.Solid Microneedles for Transdermal Delivery of Amantadine Hydrochloride and Pramipexole Dihydrochloride.An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease.Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease.New treatments for levodopa-induced motor complications.Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.New and emerging medical therapies in Parkinson's disease.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.Nondopaminergic treatments for Parkinson's disease: current and future prospects.Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective.Non-human primate models of PD to test novel therapies.Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.Striatal cholinergic interneurons and Parkinson's disease.ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.A Case Report of Severe Delirium after Amantadine Withdrawal Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).Levodopa: A new look at an old friend.Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease.Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.Safinamide: an add-on treatment for managing Parkinson's disease.Motor Complications of Dopaminergic Medications in Parkinson's Disease.Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease

P2860

Q24186581-04876CED-C0A4-48CA-8119-D8E27625AC97 Q26740905-29AB0B10-B52B-4743-A7FC-7FA034D0D45A Q27025683-18E90F75-3107-4137-8F6E-B1DD4E53F667 Q33627771-0C4933CE-D920-47A4-BE52-DB828812CA02 Q34554401-1578A064-F0D3-45F5-B437-65E819441124 Q35794829-11B95BCE-009C-4E47-9183-DAAA6BF9D40C Q36376607-E93C484D-C1D7-428D-BC6E-4F2131B0D406 Q37344109-44EA6993-4CBB-417F-80C8-0082D8A5DEE9 Q38375701-2463B34F-A8A9-45F8-B392-F9FA00CFDBD5 Q38532889-FBFE9695-2AE7-4589-8EBE-985920CC945A Q38570434-D0D1DCAE-72B2-4A67-8498-F5A14AB8FE87 Q38636630-91CC00BB-0C70-4CB1-904E-9CF750407774 Q38658203-B22F698B-1A4E-4FFA-86F1-858323A32B01 Q38718194-3B8E105B-F13A-484E-982E-85C8C90BD0D3 Q38811387-8DC8D079-841A-42FB-A294-12E70311C6F7 Q38817972-761DB4AD-EE22-4F2C-937F-5FF9BE7CB147 Q38845546-1B107885-7AE8-43CB-8DB6-F6C7274F6678 Q38947507-48DF3C41-4AD3-4190-8B8D-C25C706878A4 Q39229450-61ECD536-5690-491E-B997-312F34897EC7 Q39324877-2262B3A3-3988-44EA-8965-24C65488739D Q39325939-12B3265E-CE70-48BD-AC22-DC20E3F2935A Q39414543-67B65825-9B7E-46E6-B0C8-0354D0EBE00E Q41824342-CA070BEA-6BDB-4830-B7D3-737953EB2CD7 Q42210942-7E12A502-06D1-4566-A1D6-82D75B9B73FF Q46280394-2E648E99-12B1-460B-9851-8DCFD0C4C935 Q46641045-F4B8D967-90B6-462B-807F-AC36CE14786F Q47948932-6E5F8CAA-C7EC-44A8-A5C8-7BA7D19F75BD Q48177380-C0B0FE93-C8E8-46C3-B6A4-3CAFA16D5E70 Q52562719-AA4AD0BF-C835-40A3-86FB-76BA61053CE6 Q52658932-27B69A97-0F24-418E-AA8B-986FD2C40C26 Q52804779-6782DA9B-B158-4482-97C0-FBC2FA7C6A8B Q55279095-7866CB66-0848-4F75-94B4-35C42DCDB701 Q55285379-9A9B4FB0-C84E-4910-B864-8C911319A9D0 Q55474333-82CAD03E-0406-48E3-A5E7-E176FBD04DA3 Q58700802-01373B6A-7B86-411D-A345-D73B6A3FAC18

P2860

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)

http://www.wikidata.org/entity/Q37257345

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 February 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Amantadine extended release fo ...... kinson's disease (EASED Study)

@en

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease

@nl

type

label

Amantadine extended release fo ...... kinson's disease (EASED Study)

@en

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease

@nl

prefLabel

Amantadine extended release fo ...... kinson's disease (EASED Study)

@en

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease

@nl

P1433

Q37257345-9E2120CF-B677-472F-85CD-D57FCE1D0211

P1476

Q37257345-DCF150DE-4003-4D05-9431-57D9FE788F06

P2093

Q37257345-19372B62-FB6A-44E7-B961-2D56BA55D3B4

Q37257345-26A522BE-2FC8-48C2-900B-60B524BC9C2D

Q37257345-3CCBC7A0-4A34-4D28-A651-93E56CAD7BF6

Q37257345-6B8DD6B2-12D3-4069-A215-EF9C32AE9CFF

Q37257345-8BB3B116-8D64-49DF-979A-F9E6CB4896A1

Q37257345-ABCA23B2-5796-49BD-A81C-245D75810694

Q37257345-DAF6A8FE-63BA-4242-80EB-02840D914EEC

Q37257345-DF67665D-F3D4-48F4-9CB9-79A4AF90B885

P2860

Q37257345-0BCAEBC0-5B01-4711-8219-807B38A2375D

Q37257345-27865097-43CD-438B-902C-8E84A0103476

Q37257345-2BC74A1F-0C32-4E6A-9631-6E6C54C0B466

Q37257345-4B2E27F9-05A3-4121-AC16-C23B062BEE3E

Q37257345-574C7963-D7EB-4E08-9356-E7AD909E1FCE

Q37257345-6D220BA4-7E46-4FBB-AB78-85BA0ABE5780

Q37257345-716C5D0D-32D7-4E6D-9294-B291829F59BA

Q37257345-868BE460-4C29-4750-9AFD-3801AB81C2CC

Q37257345-AF024A42-9EC7-4CF9-9897-74C85441B3CA

Q37257345-D814ADFA-739D-47FB-8A2A-9F1CFAC9C534

P304

Q37257345-41F10554-6DD8-429F-B02B-6D70194B41B5

P31

Q37257345-83F77654-6D86-4CAC-8E3D-75FAAD78A45F

P356

Q37257345-AABD7DAD-7982-4258-BB15-5ED54964299A

P407

Q37257345-2145BCE8-89A7-41E5-836E-571B9EA65457

P433

Q37257345-B94F7FB6-F2BD-4DAC-8F68-C26C7DFB07C0

P478

Q37257345-97177430-214F-4917-850C-B813DCC2515F

P50

Q37257345-39466C8A-D045-47C0-B79D-5767EB21789C

Q37257345-9A8FF0F4-F166-4A50-BE4D-5A43691AB9C9

Q37257345-E41A8CEB-2A71-44BE-AC2F-416BBBA5456A

P577

Q37257345-FC8D6EE0-1B6B-445F-A758-5D780DA4EF7C

P5875

Q37257345-DE58BBD2-2FE1-4F24-A55E-F41D790779AF

P698

Q37257345-E7081B29-F948-4F34-90FB-71CFDABFC18A

P921

Q37257345-052E4A2E-C7A3-4577-A767-CDB33B6A9A5D

Q37257345-1004F533-35D5-4A84-B324-DC4ADA7BF321

Q37257345-2EC5B783-B719-4374-BFFE-15AC216F7C90

P932

Q37257345-7D7A53FB-C51D-4775-8C6D-7C59BE4E9BA8

P356

P1433

Movement Disorders

P1476

Amantadine extended release fo ...... kinson's disease (EASED Study)

@en

P2093

April E Ruby

http://www.w3.org/2001/XMLSchema#string

Daniel Truong

http://www.w3.org/2001/XMLSchema#string

Gregory T Went

http://www.w3.org/2001/XMLSchema#string

Kapil Sethi

http://www.w3.org/2001/XMLSchema#string

Lynn Struck

http://www.w3.org/2001/XMLSchema#string

Mary Jean Stempien

http://www.w3.org/2001/XMLSchema#string

Natalie L McClure

http://www.w3.org/2001/XMLSchema#string

Stuart Isaacson

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults.

Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.

Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms

Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores.

Which dyskinesia scale best detects treatment response?

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.

A 12-year population-based study of psychosis in Parkinson disease.

Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.

P304

788-795

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.26159

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Robert A Hauser

Caroline M Tanner

P577

2015-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272029768

http://www.w3.org/2001/XMLSchema#string

P698

25650051

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

5024015

http://www.w3.org/2001/XMLSchema#string